Medication info

Metronidazole Injection (Metronidazole Preparation)

Prescription medication
Ingredient · strength
Metronidazole›5000mg / 100mL
Manufacturer / importer
Daehan Pharmaceutical Co., Ltd.
Appearance
A colorless to pale yellow transparent liquid filled in a colorless transparent glass or plastic container.
Packaging
100 milliliters per bottle, 100 milliliters per pack
Approval status
Active

MFDS item code 199500289 · Notified 1995.03.09 · Insurance code 645101422

Summary

Main use
Treatment of anaerobic bacterial infections, prevention of postoperative infections, and treatment of trichomoniasis and amebiasis
Who uses it
Adults · Children
Adult dosage
(Tablets) Trichomoniasis: The usual adult dose of metronidazole is 250 mg orally twice daily for 10 days. Treatment of anaerobic bacterial infections: The usual adult dose of this medicine is 500 mg orally 3 ∼ 4 times daily. Do not exceed the maximum daily dose of 4 g; treatment is generally given for 7 ∼ 10 days. Postoperative prophylaxis of anaerobic bacterial infections: The usual adult initial dose of this medicine is 1 g, followed by 250 mg orally 3 times daily. Amebiasis: The usual adult dose of this medicine is 500 ∼ 750 mg orally 3 times daily for 5 ~ 10 days. (Injection) Administer the following dose of this medicine by slow intravenous injection at a rate of 25 mg (5 mL) per minute. When the patient's condition improves, switch to an oral dosage form as soon as possible. Treatment of anaerobic bacterial infections: Adults: Administer 500 mg (100 mL) of metronidazole intravenously every 8 hours. When oral administration becomes possible, switch to oral metronidazole 500 mg 3 times daily. The total duration of injection therapy should not exceed 7 days; however, extension of treatment may be considered based on clinical and bacteriological assessment. Prophylaxis of postoperative infections caused by anaerobic bacteria (use of this regimen is generally limited to 24 hours, and no longer than 48 hours): In adults, administer 500 mg (100 mL) of this medicine intravenously every 8 hours immediately before, during, or after surgery. When oral administration becomes possible, switch to oral metronidazole 250 mg 3 times daily.
Children's dosage
Treatment of anaerobic bacterial infections, children aged 12 years and older: Administer 500 mg (100 mL) of metronidazole intravenously every 8 hours. When oral administration becomes possible, switch to oral metronidazole 500 mg 3 times daily. The total duration of injection therapy should not exceed 7 days; however, extension of treatment may be considered based on clinical and bacteriological assessment. Treatment of anaerobic bacterial infections, children under 12 years: Administer 3 times daily. The dose for each intravenous injection is 7.5 mg (1.5 mL) of this medicine per kg of body weight; the dose for each oral administration is also 7.5 mg of metronidazole per kg of body weight. Treatment of anaerobic bacterial infections, children under 8 weeks: Administer 2 times daily. Prophylaxis of postoperative infections caused by anaerobic bacteria, children aged 12 years and older: Administer 500 mg (100 mL) of this medicine intravenously every 8 hours immediately before, during, or after surgery. When oral administration becomes possible, switch to oral metronidazole 250 mg 3 times daily. Prophylaxis of postoperative infections caused by anaerobic bacteria, children under 12 years: The preoperative intravenous dose is 20~30 mg of this medicine per kg of body weight as a single dose. Prophylaxis of postoperative infections caused by anaerobic bacteria, premature infants: The preoperative intravenous dose is 10mg of this medicine per kg of body weight as a single dose.

Ingredients

Manufacturer
Daehan Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of anaerobic bacterial infections, prevention of postoperative infections, and treatment of trichomoniasis and amebiasis

  • Trichomoniasis
  • intra-abdominal infections
  • peritonitis
  • intra-abdominal abscess
  • liver abscess
  • skin and soft tissue infections
  • endometritis
  • myometritis
  • tubo-ovarian abscess
  • bacterial sepsis
  • bone and joint infections
  • central nervous system infections
View approved original text

This medicine is used to treat parasitic infections such as trichomoniasis and amoebiasis. It also treats various infections caused by anaerobic bacteria, including peritonitis, skin and soft tissue infections, uterine and pelvic infections, and pneumonia, and is effective in preventing anaerobic infections that may occur after surgery. In particular, it is used for severe infections such as sepsis, brain abscess, pulmonary abscess, and osteomyelitis, helping to improve symptoms. This drug is widely used for the treatment of various medical and surgical infections and plays an important role in the treatment and prevention of infections.

Dosage and Administration

Adult dosage

(Tablets) Trichomoniasis: The usual adult dose of metronidazole is 250 mg orally twice daily for 10 days. Treatment of anaerobic bacterial infections: The usual adult dose of this medicine is 500 mg orally 3 ∼ 4 times daily. Do not exceed the maximum daily dose of 4 g; treatment is generally given for 7 ∼ 10 days. Postoperative prophylaxis of anaerobic bacterial infections: The usual adult initial dose of this medicine is 1 g, followed by 250 mg orally 3 times daily. Amebiasis: The usual adult dose of this medicine is 500 ∼ 750 mg orally 3 times daily for 5 ~ 10 days. (Injection) Administer the following dose of this medicine by slow intravenous injection at a rate of 25 mg (5 mL) per minute. When the patient's condition improves, switch to an oral dosage form as soon as possible. Treatment of anaerobic bacterial infections: Adults: Administer 500 mg (100 mL) of metronidazole intravenously every 8 hours. When oral administration becomes possible, switch to oral metronidazole 500 mg 3 times daily. The total duration of injection therapy should not exceed 7 days; however, extension of treatment may be considered based on clinical and bacteriological assessment. Prophylaxis of postoperative infections caused by anaerobic bacteria (use of this regimen is generally limited to 24 hours, and no longer than 48 hours): In adults, administer 500 mg (100 mL) of this medicine intravenously every 8 hours immediately before, during, or after surgery. When oral administration becomes possible, switch to oral metronidazole 250 mg 3 times daily.

Children's dosage

Treatment of anaerobic bacterial infections, children aged 12 years and older: Administer 500 mg (100 mL) of metronidazole intravenously every 8 hours. When oral administration becomes possible, switch to oral metronidazole 500 mg 3 times daily. The total duration of injection therapy should not exceed 7 days; however, extension of treatment may be considered based on clinical and bacteriological assessment. Treatment of anaerobic bacterial infections, children under 12 years: Administer 3 times daily. The dose for each intravenous injection is 7.5 mg (1.5 mL) of this medicine per kg of body weight; the dose for each oral administration is also 7.5 mg of metronidazole per kg of body weight. Treatment of anaerobic bacterial infections, children under 8 weeks: Administer 2 times daily. Prophylaxis of postoperative infections caused by anaerobic bacteria, children aged 12 years and older: Administer 500 mg (100 mL) of this medicine intravenously every 8 hours immediately before, during, or after surgery. When oral administration becomes possible, switch to oral metronidazole 250 mg 3 times daily. Prophylaxis of postoperative infections caused by anaerobic bacteria, children under 12 years: The preoperative intravenous dose is 20~30 mg of this medicine per kg of body weight as a single dose. Prophylaxis of postoperative infections caused by anaerobic bacteria, premature infants: The preoperative intravenous dose is 10mg of this medicine per kg of body weight as a single dose.

Precautions

This drug has been reported to cause tumor occurrence in rodent animal experiments and should not be used unnecessarily. In patients with cocaine syndrome, this drug can cause severe hepatotoxicity or acute liver failure, so liver function tests should be performed and caution is warranted. Patients with hypersensitivity to this drug, blood diseases, organic nervous system diseases, in early pregnancy, or those taking certain medications should not be treated with this drug. Severe adverse reactions can occur when taken with alcohol, so alcohol intake should be avoided for at least 3 days during and after administration. Patients with liver dysfunction, those in late pregnancy, central nervous system diseases, and those with impaired heart or kidney function should use this drug cautiously. This drug can cause various side effects in the digestive system, blood system, skin, nervous system, etc., so any unusual symptoms should be reported to healthcare professionals immediately. Patients with severe liver disease may require dose adjustments as this drug and its metabolites can accumulate in the body, and regular monitoring during treatment is recommended. When taking this drug, confusion, drowsiness, hallucinations, seizures, visual disturbances, etc., can occur, so driving or operating machinery should be avoided. This drug can affect blood coagulation, so patients on anticoagulants need to monitor blood levels for dose adjustments. There are interactions with lithium, alcohol, disulfiram, some anticonvulsants, immunosuppressants, etc., so it is essential to inform about any medications being taken. During pregnancy, it may affect the fetus, so especially early pregnant women should avoid use, and breastfeeding should be suspended during treatment. In case of overdose, there is no specific antidote, and general treatment should be received. This drug should not be mixed when used with other antibiotics and must be used specifically for intravenous administration during infusion.

Side effects

  • Elevated serum amylase
  • abdominal pain
  • nausea
  • vomiting
  • diarrhea
  • oral mucositis
  • taste disturbance
  • loss of appetite
  • reversible pancreatitis
  • leukopenia
Show 53 more
  • neutropenia
  • agranulocytosis
  • thrombocytopenia
  • rash
  • itching
  • flushing
  • urticaria
  • fever
  • angioedema
  • anaphylactic shock
  • pustular rash
  • erythema multiforme
  • aseptic meningitis
  • headache
  • seizures
  • dizziness
  • ataxia
  • syncope
  • convulsive seizures
  • peripheral sensory neuropathy
  • encephalopathy
  • confusion
  • subacute cerebellar syndrome
  • ataxia
  • speech impairment
  • gait disturbance
  • tremor
  • venous thrombosis
  • psychiatric disorders
  • depressed mood
  • diplopia
  • myopia
  • optic neuropathy
  • elevated liver enzyme levels
  • bile duct obstruction
  • hepatitis
  • jaundice
  • mucocutaneous syndrome
  • toxic epidermal necrolysis
  • eosinophilia
  • drug reactions
  • acute generalized pustular exanthema
  • vesicular dermatitis
  • fixed drug eruption
  • hearing impairment
  • hearing loss
  • tinnitus
  • fever
  • drowsiness
  • glossitis
  • dry lips
  • hematuria
  • arthralgia

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container that can block light, and the temperature should be kept between 1 to 30 degrees Celsius at room temperature. This way of storage helps maintain the drug's efficacy and safety.

Appearance and packaging

Appearance

A colorless to pale yellow transparent liquid filled in a colorless transparent glass or plastic container.

Package unit

100 milliliters per bottle, 100 milliliters per pack

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.